tbuckley/cabot-search huggingface dataset:
Association of Family Ratings of Quality of End-of-Life Care With Stopping Dialysis Treatment and Receipt of Hospice Services
Authors: Claire A. Richards, Paul L. Hebert, Chuan-Fen Liu, Mary Ersek, Melissa W. Wachterman, Leslie L. Taylor, Lynn F. Reinke, Ann M. O’Hare
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Approximately 1 in 4 patients receiving maintenance dialysis for end-stage renal disease eventually stop treatment before death. Little is known about the association of stopping dialysis and quality of end-of-life care. <h3>Objectives</h3> To evaluate the association of stopping dialysis before death with family-rated quality of end-of-life care and whether this association differed according to receipt of hospice services at the time of death. <h3>Design, Setting, and Participants</h3> This survey study included data from 3369 patients who were treated with maintenance dialysis at 111 Department of Veterans Affairs medical centers and died between October 1, 2009, to September 30, 2015. Data set construction and analyses were conducted from September 2017 to July 2019. <h3>Exposure</h3> Cessation of dialysis treatment before death. <h3>Main Outcomes and Measures</h3> Bereaved Family Survey ratings. <h3>Results</h3> Among 3369 patients included, the mean (SD) age at death was 70.6 (10.2) years, and 3320 (98.5%) were male. Overall, 937 patients (27.8%) stopped dialysis before death and 2432 patients (72.2%) continued dialysis treatment until death. Patients who stopped dialysis were more likely to have been receiving hospice services at the time of death than patients who continued dialysis (544 patients [58.1%] vs 430 patients [17.7%]). Overall, 1701 patients (50.5%) had a family member who responded to the Bereaved Family Survey. In adjusted analyses, families were more likely to rate overall quality of end-of-life care as excellent if the patient had stopped dialysis (54.9% vs 45.9%; risk difference, 9.0% [95% CI, 3.3%-14.8%];<i>P</i> = .002) or continued to receive dialysis but also received hospice services (60.5% vs 40.0%; risk difference, 20.5% [95% CI, 12.2%-28.9%];<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> This survey study found that families rated overall quality of end-of-life care higher for patients who stopped dialysis before death or continued dialysis but received concurrent hospice services. More work to prepare patients for end-of-life decision-making and to expand access to hospice services may help to improve the quality of end-of-life care for patients with end-stage renal disease.
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
Authors: A.R. Ferreira, A. Di Meglio, B. Pistilli, A.S. Gbenou, M. El-Mouhebb, S. Dauchy, C. Charles, F. Joly, S. Everhard, M. Lambertini, C. Coutant, P. Cottu, F. Lerebours, T. Petit, F. Dalenc, P. Rouanet, A. Arnaud, A. Martin, J. Berille, P.A. Ganz, A.H. Partridge, S. Delaloge, S. Michiels, F. Andre, I. Vaz-Luis
Journal: Annals of Oncology (2019)
Bone Marrow Interaction in Multiple Myeloma Pathogenesis: Phenotypical Analysis, Kinetics and Novel Therapy Approaches Based On CXCR4 Inhibition.
Authors: Johannes Waldschmidt, Dagmar Wider, Marie Follo, Josefina Udi, Martina Kleber, Joschka Lorenz, Gabriele Ihorst, Ralph Wäsch, Monika Engelhardt
Journal: Blood (2012)
Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, Lilia Taningco, Weiping Deng, Hans D Menssen, Hagop M. Kantarjian
Journal: Blood (2015)
Chromosome Study On Chronic Lymphocytic Leukemia Using CpG- Oligodeoxynucleotide as Immunostimulant Agent.
Authors: Yafang Wu, Yongquan Xue, Li Yao, Hui Jiang, Jun Zhang, Juan Shen, Jinlan Pan, Yong Wang, Shuxiao Bai, Suning Chen
Journal: Blood (2009)
ALX-0081 Nanobody™, an Engineered Bivalent Anti-Thrombotic Drug Candidate with Improved Efficacy and Safety as Compared to the Marketed Drugs.
Authors: Karen Silence, Heidi Jonckheere, Peter Casteels, Jan Roodt, Muriel Meiring, Seb Lamprecht, Martin IJsseldijk, Kristi de Smet, Bob van der Jeugt, Flip de Groot, Torsten Dreier
Journal: Blood (2006)
Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.
Authors: Rony Schaffel, Craig H. Moskowitz, Jocelyn C. Maragulia, Carol S. Portlock, Cyrus V. Hedvat, Andrew D. Zelenetz
Journal: Blood (2009)
Pretreatment Serum Level of 15-KDa Granulysin Might Predict Recurrence and Survival of Diffuse Large B Cell Lymphoma Patients Treated by R-CHOP Regimen
Authors: Yong Park, Yoon Ji Choi, Se Jong Park, Se Ryeon Lee, Hwa Jung Sung, Kyong Hwa Park, Seok Jin Kim, Chul Won Choi, Byung Soo Kim, Kwang Yoon Jung
Journal: Blood (2010)
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Authors: Lieneke F. M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Deepak Balak, Margreet L. E. Romeijn, Tessa Kouwenhoven, Marijke Kamsteeg, Barbara Giovannone, Julia Drylewicz, Cynthia Catalina Aurora van Amerongen, Evelien M. Delemarre, Edward F. Knol, Femke van Wijk, Stefan Nierkens, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller
Journal: Allergy (2019)

Abstract Introduction Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce. Objective To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice. Methods Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks). Results In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased. Conclusion Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting.
Polymorphisms of <i>MTHFR</i> and <i>TYMS</i> predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancer
Authors: Shaoyan Lin, Jian Yue, Xiuwen Guan, Peng Yuan, Jiayu Wang, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Shanshan Chen, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Journal: Cancer Communications (2019)

Abstract Background Breast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand‐foot syndrome (HFS) is a common adverse effect of capecitabine. In this study, we investigated the association between single nucleotide polymorphisms (SNPs) in genes involved in capecitabine metabolism pathways and capecitabine‐induced HFS in Chinese patients with MBC to identify some predictive genetic biomarkers. Methods We selected 3 genes involved in capecitabine metabolism and screened genetic variants in these target genes. We genotyped a total of 22 SNPs in the thymidylate synthase gene ( TYMS ), the methylene tetrahydrofolate reductase gene ( MTHFR ), and the ribonucleotide reductase M1 gene ( RRM1 ) in 342 MBC patients treated with capecitabine‐based chemotherapy. The genotype distributions of each SNP in patients with and without HFS were assessed using Pearson's χ 2 test, and the relationship between HFS and genotypes of SNPs was determined using logistic regression analysis. The association between SNPs and their corresponding gene expression was analyzed using the Blood expression quantitative trait loci (eQTL) browser online tools. Results We found 4 positive sites for HFS in the TYMS and MTHFR genes: TYMS rs2606241 ( P = 0.022), TYMS rs2853741 ( P = 0.019), MTHFR rs3737964 ( P = 0.029), and MTHFR rs4846048 ( P = 0.030). Logistic regression analyses showed that the genotype AG of MTHFR rs3737964 [odds ratio (OR) = 0.54, 95% confidence interval (CI) 0.31–0.97, P = 0.038] and MTHFR rs4846048 (OR = 0.54, 95% CI 0.30–0.98, P = 0.042) were protective factors of HFS, whereas the genotype CT of TYMS rs2853741 (OR = 2.25, 95% CI 1.31–3.87, P = 0.012) increased the risk of HFS. The association between the genotype GT of TYMS rs2606241 (OR = 1.27, 95% CI 0.73–2.23, P = 0.012) and HFS was uncertain. Further eQTL analyses confirmed that the alleles of rs3737964 and rs4846048 affected the gene expression levels of MTHFR in cis . Conclusions We have identified four potentially useful pharmacogenetic markers, TYMS rs2606241, TYMS rs2853741, MTHFR rs3737964, and MTHFR rs4846048 to predict capecitabine‐induced HFS in MBC patients.
Multiple Myeloma Cell Induction of GFI-1 in Stromal Cells Suppresses Osteoblast Differentiation in Patients with Myeloma.
Authors: Sonia D'Souza, Davide Del Prete, Flavia Esteve, Benedicte Sammut, Shibing Yu, Guozhi Xiao, Deborah Galson, G. David Roodman
Journal: Blood (2009)
Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
Authors: Eva Hoster, Michael Unterhalt, Bernd Metzner, Michael Pfreundschuh, Peter Staib, Georg Jacobs, Hans Walter Lindemann, Wolf-Dieter Ludwig, H. Tilman Steinmetz, Lorenz Truemper, Hannes Wandt, Christian Buske, Martin H. Dreyling, Wolfgang Hiddemann
Journal: Blood (2011)
Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).
Authors: Gloria Mattiuzzi, Jorge Cortes, Deborah McCue, B. Nebiyou Bekele, Lianchun Xiao, Gautam Borthakur, Hagop Kantarjian
Journal: Blood (2009)
Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells
Authors: Xiaojia Niu, Jianyun Zhao, Jun Ma, Chengzhi Xie, Holly Edwards, Guan Wang, J. Timothy Caldwell, Roland Chu, Zhihong Wang, Hai Lin, Jeffrey W Taub, Yubin Ge
Journal: Blood (2015)
Targeted Radiotherapy in the Conditioning Prior to Haematopoietic Stem Cell Transplantation: Results of a Phase I Radiation Dose Escalation Study Using Yttrium-90-Labelled Anti-CD66 Monoclonal Antibody Demonstrating High BM Uptake of Radiation.
Authors: Kim Orchard, Margaret Cooper, Valerie Lewington, Maria Tristram, Maureen Zivanovic, James Thom, Syed Quadri, Deborah Richardson, Louise Causer, Peter Johnson
Journal: Blood (2005)
A Phase 2 Open-Label, Sequential-Cohort, Dose-Escalation Study of AMG 531 in Japanese Patients with Chronic Immune Thrombocytopenic Purpura (ITP).
Authors: Yukari Shirasugi, Kiyoshi Ando, Satoshi Hashino, Toshiro Nagasawa, Yoshiyuki Kurata, Yuji Kishimoto, Koji Iwato, Yusuke Sonehara, Masayuki Ohkura, Tomoko Ohtsu, Janet L. Nichol
Journal: Blood (2007)
Peripheral Stem Cell Mobilization with Chemotherapy + G-CSF Priming in a Large Series of Patients with Lymphoma Candidates to Autologous Transplantation. An Analysis of Baseline and Ongoing Predictors of Failure or Suboptimal Stem Cell Collection.
Authors: Enrico Morello, Camillo Almici, Luca Arcaini, Liliana Baushi, Barbara Botto, Andrea Castelli, Annamaria Nosari, Gianmatteo Pica, Francesco Ripamonti, Flavia Salvi, Angelo Michele Carella, Gianluca Gaidano, Alessandro Levis, Enrica Morra, Umberto Vitolo, Rossi Giuseppe
Journal: Blood (2009)
A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival.
Authors: Dirk Hose, Jean-Francois Rossi, Carina Ittrich, John deVos, Axel Benner, Thierry Reme, Jelena Bila, Veronique Grau, Marc Raab, Philine Kaukel, Eric Jourdan, Marion Moos, Ann-Cathrin Theil, Anna Jauch, Hartmut Goldschmidt, Bernard Klein, Friedrich W. Cremer
Journal: Blood (2004)
Cardiometabolic and Hemostatic Profiles of Women Carriers of Hemoglobin Variants Using Combined Oral Contraceptives
Authors: Junia Raquel Dutra Ferreira, Caroline Conceição Guarda, Rayra Pereira Santiago, Luane Rocha, Jessica SANTOS Ferreira, Luís Araújo, Barbara Mota, Thassila Nogueira Pitanga, Milena Magalhães Milena, Magda Seixas Carvalho, Elisangela Vitoria Adorno, Marilda Souza Goncalves
Journal: Blood (2016)
Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia
Authors: Huimin Geng, Donna Neuberg, Elisabeth Paietta, Xutao Deng, Yushan Li, Yuan Xin, Janis Racevskis, Rhett Ketterling, Susan M Richards, Martin S. Tallman, Jacob M. Rowe, Mark R. Litzow, Olivier Elemento, Ari M. Melnick
Journal: Blood (2010)
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.
Authors: PierLuigi Tazzari, Veronica Papa, Francesca Ricci, Francesca Chiarini, Camilla Evangelisti, Giovanni Martinelli, Andrea Bontadini, James McCubrey, Alberto M. Martelli
Journal: Blood (2008)
The “zipline” technique for endoscopic transpapillary biliary biopsy
Authors: Tsuyoshi Hamada, Naminatsu Takahara, Yousuke Nakai, Sachiko Kanai, Tomotaka Saito, Kazuhiko Koike
Journal: Endoscopy (2019)

Endoscopic transpapillary biopsy has been the cornerstone of tissue acquisition from the biliary epithelium [1] [2]. However, targeting biliary lesions using standard biopsy forceps is occasionally difficult [3], and wire-guided biopsy forceps are not commonly available. Herein, we present a technique for biliary biopsy with a simple modification of a widely used biopsy forceps.
Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo
Authors: Sylvia Herter, Idit Sagiv-Barfi, Cariad Chester, Mohith Sadaram, Jonathan Hebb, Debra K Czerwinski, Narendiran Rajasekaran, Marina Bacac, Pablo Umana, Ron Levy, Christian Klein, Holbrook E Kohrt
Journal: Blood (2014)
Inverse PAR1 Activity of Hematopoietic Stem Cells and BM Stromal Cells Mediates G-CSF-Induced Mobilization By Regulation of Nitric Oxide Generation
Authors: Neta Nevo, Shiri Gur-Cohen, Orit Kollet, Francesca Avemaria, Seymen Avci, Tomer Itkin, Sagarika Chakrabarty, Tzila Zuckerman, Benjamin Brenner, Yona Nadir, Irina Zaidman, Myriam Ben Arush, Charles Esmon, Wolfram Ruf, Tsvee Lapidot
Journal: Blood (2016)
Ascorbic Acid, Dehydroascorbic Acid, and Diketogulonic Acid of Transplanted Melanomas and of Other Tumors of the Mouse
Authors: Helen M. Dyer, Helen E. Ross
Journal: JNCI Journal of the National Cancer Institute (1950)

Ascorbic Acid, Dehydroascorbic Acid, and Diketogulonic Acid of Transplanted Melanomas and of Other Tumors of the Mouse Helen M. Dyer, Helen M. Dyer Search for other works by this author on: Oxford Academic PubMed Google Scholar Helen E. Ross Helen E. Ross National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 2, October 1950, Pages 313–318, https://doi.org/10.1093/jnci/11.2.313 Published: 01 October 1950 Article history Received: 06 July 1950 Published: 01 October 1950
Evaluation of the Concordance of Two Free Light Chains Assays to Identify High Risk Smoldering Myeloma Patients.
Authors: Caroline Moreau, Emmanuel Rouger, Basile Henriot, Martine Escoffre, Martine Sebillot, Thierry Lamy, Stéphane Minvielle, Herve Avet Loiseau, Olivier Decaux
Journal: Blood (2016)
Association of Gastrointestinal Chemotoxicity to the Performance Status of Breast Cancer Patients: A Preliminary Study
Authors: Fernando Dharmaraja, Olivia J.D.A. Saroso, Wilson M. Raffaello, Julang Fahman, Felix Wijovi, Helenia Putri, Devina Adelia Halim, Elizabeth Celine, Regina Nathania, Andree Kurniawan
Journal: Annals of Oncology (2019)
Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.
Authors: Donna E. Reece, Esther Masih-Khan, Christine Chen, Lisa Wang, Saima Dean, Vishal Kukreti, Joseph R. Mikhael, Suzanne Trudel, Robert Knight, Jerome Zeldis
Journal: Blood (2006)
Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.
Authors: ZiYi Lim, Aloysius Ho, Michelle Kenyon, Stephen Devereux, Rafael Duarte, Antonio Pagliuca, Ghulam Mufti
Journal: Blood (2005)
AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting.
Authors: Yoshiyuki Takahashi, Abdul Tawab, Roger Kurlander, Mohamed Elshal, Charles Bolan, E.J. Read, Susan Leitman, J. Philip McCoy, Andreas Lundqvist, Erkut Bahceci, Richard Childs
Journal: Blood (2005)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody® ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.
Authors: Khalid Abd-Elaziz, Pieter W. Kamphuisen, Christophe Lyssens, Mariska Reuvers, Izaak den Daas, Femke Van Bockstaele, Kristof Vercruysse, Hans Ulrichts, Judith Baumeister, Patricia Crabbe, Veerle Compernolle, Josefin-Beate Holz
Journal: Blood (2009)
A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.
Authors: Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Harry Paul Erba, Ronald Sobecks, Anjali Advani, Julie Nichols, Josephine Chan, Matt Kalaycio
Journal: Blood (2006)
Allogeneic Hematopoietic Stem Cell Transplantation for Adult AML Patients with Granulocytic Sarcoma
Authors: Hiroaki Shimizu, Takayuki Saitoh, Masatsugu Tanaka, Takehiko Mori, Nobutaka Kawai, Toru Sakura, Yoshinobu Kanda, Chiaki Nakaseko, Shingo Yano, Hiroyuki Fujita, Shin Fujisawa, Shuichi Miyawaki, Heiwa Kanamori, Shinichiro Okamoto
Journal: Blood (2011)
Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)
Authors: Ana García-Noblejas, Eulogio Conde, Alejandro Martín, María Jesús Vidal, Rafael Rojas, Carlos Grande, María José Ramirez, Jimena Cannata-Ortiz, Juan Carlos García-Ruiz, Javier Briones, Andrés Lopez, Pablo Ríos Rull, Victor Noriega, Guillermo Deben, Eva González Barca, Sonia González de Villambrosia, Jose Javier Ferreiro, Juan José Lahuerta, Maria Dolores Caballero, Reyes Arranz
Journal: Blood (2014)
High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.
Authors: Anna Vanazzi, Pier Francesco Ferrucci, Chiara Grana, Marta Cremonesi, Margherita Clerici, Davide Radice, STefano Papi, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli
Journal: Blood (2006)
Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion
Authors: Brian C Shaffer, Judith Leitner, Adrian Wiestner, Michael R. Bishop, Steven Z. Pavletic, Ronald E. Gress, Peter Steinberger, Sivasubramanian Baskar, Christoph Rader
Journal: Blood (2012)
IFN-γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia.
Authors: Dong Hwan Dennis Kim, Jee Hyun Kong, Silvia Park, Chul Won Jung, Lakshmi Sriharsha, Wei Xu, Suzanne Kamel-Reid, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Jeffrey H. Lipton
Journal: Blood (2009)
Intubation Guidance Tool Earns Top Prize
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma
Authors: Robert Kridel, King Tan, Abdulwahab J. Al-Tourah, Alden A. Moccia, David W. Scott, Graham W. Slack, Joseph M. Connors, Laurie H. Sehn, Christian Steidl, Randy D. Gascoyne
Journal: Blood (2012)
C-Terminal-Truncating ASXL1 Mutations Induce MDS Via Inhibition Of PRC2
Authors: Daichi Inoue, Jiro Kitaura, Katsuhiro Togami, Koutarou Nishimura, Yutaka Enomoto, Tomoyuki Uchida, Yuki Kagiyama, Kimihito Cojin Kawabata, Fumio Nakahara, Toshihiko Oki, Hironori Harada, Takahiro Ochiya, Hiroyuki Aburatani, Hiroshi Kimura, Felicitas Thol, Michael Heuser, Ross L. Levine, Omar Abdel-Wahab, Toshio Kitamura
Journal: Blood (2013)
Efficacy of information prescription booklet and video material on patient adherence for chemothrapy induced dermopathy
Authors: Junya Sato, Hiroshi Ishikawa, Yoko Yasuda, Yuki Yamawaki, Megumi Endo, Kazuko Nakajima, Akio Kiyohara, Michihiro Shino
Journal: Annals of Oncology (2019)
Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT
Authors: Jonathan Canaani, Eric Beohou, Myriam Labopin, Gerard Socie, Anne Huynh, Liisa Volin, Jan J. Cornelissen, Noel Milpied, Tobias Gedde-Dahl, Eric Deconinck, Jeremy Delage, Didier Blaise, Mohamad Mohty, Arnon Nagler
Journal: Blood (2016)
Hematopoietic Peripheral Circulating Blood Stem Cells As an Independent Marker of Good Transfusion Management in Patients with Beta-Thalassemia
Authors: Mariasanta Napolitano, Calogera Gerardi, Anna Di Lucia, Pietro Andrea Accardo, Luigi Rizzuto, Ferraro Maria, Giuseppe Tarantino, Sergio Siragusa, Filippo Buscemi
Journal: Blood (2015)
The PAK Signaling System Links Rho Gtpase Activation to Platelet Lamellopodia Formation, Aggregation and Aggregate Stability Under Shear
Authors: Kristina M. Haley, Joseph E Aslan, Garth W. Tormoen, Sandra M Baker, Cassandra P. Loren, Jonathan Chernoff, Owen J.T. McCarty
Journal: Blood (2012)